We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Kromek Group Plc | LSE:KMK | London | Ordinary Share | GB00BD7V5D43 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 7.20 | 1,256,266 | 16:35:13 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 7.10 | 7.40 | 7.30 | 7.04 | 7.20 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Miscellaneous Metal Ores,nec | 17.31M | -6.1M | -0.0095 | -7.63 | 46.19M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 17:05:29 | O | 160,000 | 7.20 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 30/9/2024 | 07:00 | UK RNS | Kromek Group PLC Update on Full Year Results |
| 23/9/2024 | 07:00 | UK RNS | Kromek Group PLC Kromek selected for UK Government Framework |
| 16/9/2024 | 11:46 | ALNC |  Kromek wins GBP2 million contract with UK Ministry of Defence |
| 16/9/2024 | 07:00 | UK RNS | Kromek Group PLC Kromek awarded £2.0m contract from UK MOD |
| 21/8/2024 | 10:14 | UK RNS | Kromek Group PLC Holding(s) in Company |
| 30/7/2024 | 07:00 | UK RNS | Kromek Group PLC Kromek selected for UK Government Framework |
| 07/6/2024 | 09:20 | UK RNS | Kromek Group PLC Cancellation of outstanding Convertible Loan Notes |
| 29/5/2024 | 11:47 | ALNC | Kromek shares enjoy boost on projection of improved annual results |
| 29/5/2024 | 07:00 | UK RNS | Kromek Group PLC FY 2024 Trading Update |
| 25/4/2024 | 12:22 | ALNC | Kromek rises on USD2.9 million order from US federal customer |
Kromek (KMK) Share Charts1 Year Kromek Chart |
|
1 Month Kromek Chart |
Intraday Kromek Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 04/10/2024 | 11:51 | Kromek Group PLC | 7,151 |
| 05/1/2022 | 09:19 | Kromek Group (KMK) - Overvalued AIM mugging | 182 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-10-10 16:05:30 | 7.20 | 160,000 | 11,520.00 | O |
| 2024-10-10 15:35:13 | 7.20 | 400 | 28.80 | UT |
| 2024-10-10 15:21:25 | 7.20 | 27,882 | 2,007.50 | O |
| 2024-10-10 14:49:37 | 7.20 | 50,000 | 3,600.00 | O |
| 2024-10-10 14:49:07 | 7.37 | 15,603 | 1,149.94 | O |
| Top Posts |
|---|
Posted at 10/10/2024 09:20 by Kromek Daily Update Kromek Group Plc is listed in the Miscellaneous Metal Ores,nec sector of the London Stock Exchange with ticker KMK. The last closing price for Kromek was 7.20p.Kromek currently has 641,550,000 shares in issue. The market capitalisation of Kromek is £46,512,375. Kromek has a price to earnings ratio (PE ratio) of -7.63. This morning KMK shares opened at 7.20p |
Posted at 30/7/2024 12:18 by ark87 andrew97 - Literally what every investor here been hoping for since the IPO 11 years ago. share price was 49 back then btw!! With KMK history usually repeats itself. So right now they desperate for some hype job to get anonther placing off. What ever happened to those game changing covid detectors? |
Posted at 30/7/2024 11:16 by andrew97 I have to agree, much of the information was on the website last week. It seems something had to be done to halt the seemingless decline in price over the last few months. Results September maybe something else is coming down the tracks. |
Posted at 30/5/2024 13:36 by z1co Contract momentum builds at KromekRadiation detection technology company continues to win contracts from the medical imaging and nuclear markets. It has takeover potential too January 30, 2024 by Simon Thompson First half cash loss narrows from £2.7mn to £0.1mn Analysts push through material profit upgrades Sedgefield-based Kromek (KMK:5.8p), a radiation detection technology company, expects to report record revenue and return to cash profitability in the 12 months to 30 April 2024. The directors’ confidence is not misplaced if this week’s interim results are anything to go by. In the six-month period, Kromek won £8mn of orders including a contract worth $1.4mn (£1.1mn) from a new original equipment manufacturers (OEM) customer, an established player in the medical imaging sector in Asia. Kromek will supply its cadmium zinc telluride (CZT)-based detector modules for use in the company’s next-generation single-photon emission CT (SPECT)-based medical imaging scanners, and has won another four medical imaging orders from existing clients in recent weeks. |
Posted at 29/5/2024 13:19 by jaknife Kromek is a pile of sh-one-t. Year in, year out it pulls the wool over the eyes of amateur retail punters with some flim-flam BS only to raise funds in a discounted placing at the last minute.This time they claim that they'll be EBIDTA positive. Whoop whoop but what about actual profits? Cavendish forecast EBITDA of £1.2m for the full-year (to April 2024), which translates to a P&L loss of £5.3m. And normally KMK's cash losses exceed their P&L losses because they capitalise material expenses directly to the balance sheet (£4.8m worth last year). KMK reported cash of £3.7m at the interim stage (Oct 2023) and should burn cash of about £5m to £6m. Hence cash will run out before year end (Oct 2024) and, specifically cash will run out before they intend to publish the finals in September! Expect a discounted placing well before the finals are published. JakNife |
Posted at 05/2/2024 11:30 by brynos KROMEK GROUP PLCReleased 10:17:36 05 February 2024 RNS Number : 0345C Kromek Group PLC 05 February 2024 5 February 2024 Kromek Group plc ("Kromek" or the "Company" or the "Group") Conversion of £1.5m of Convertible Loan Notes Kromek Group plc (AIM: KMK), a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, announces that two holders of the convertible loan notes ("Loan Notes") issued in August 2022 have elected to convert them into new ordinary shares of 1 penny each in the Company ("Ordinary Shares") at conversion prices of 6.3 pence and 7.1 pence, per Ordinary Share. Including accrued interest, the Loan Note holders are converting £1,509,211 of debt into 23,639,520 new Ordinary Shares and accordingly these new Ordinary Shares have been issued and allotted by the board. The issue prices of 6.3 and 7.1 pence per new Ordinary Share represent the closing price of the Company's Ordinary Shares on AIM on 31 January 2024 and 2 February 2024, respectively, being the repayment date of the convertible loan note facilities. Application has been made for the 23,639,520 Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on or around 8.00 a.m. on 9 February 2024 ("Admission"). The new Ordinary Shares will rank pari passu with the existing shares of the Company. Following Admission, the Company's issued share capital will consist of 623,886,340 Ordinary Shares, none of which are held in treasury. Accordingly, the figure of 623,886,340 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules. |
Posted at 08/1/2024 20:31 by jaknife The recent boom in the number of shares is because of a convertible loan note. The last share conversion under the note was announced here:All is not what it seems and the directors have been deliberately deceptive on two levels. 1. Fixed Conversion Price The original RNS that announced the terms of the convertible is here: The conversion terms are described as: "The Loan Notes have a term of 18 months (with the Company having the option to extend the majority of the loan notes by three months), are senior in ranking and unsecured. The Loan Notes are convertible at investors option into ordinary shares in the capital of the Company ("Ordinary Shares") at 15 pence per Ordinary Share, representing a 30% premium to the mid-price of the Company's share price at close of business on 04 August 2022. The Loan Notes carry a coupon of 8% per annum and have a conversion date of 31 January 2024." And so you would be forgiven if you thought that the loan was convertible at 15p a share - it is not! The RNS then goes onto note: "The Loan Note holders have the right to elect to be repaid in whole or in part in Ordinary Shares at the lower of the closing mid-market price on the repayment date, and 15 pence per share." The reality of the wording is that this boils down to: "The Loan Note holders have the right to elect to be repaid in Ordinary Shares issued at the closing mid-market price on the repayment date." 2. Interest But there is a second more important deliberate deception that the directors are executing, which relates to the terms on which the interest on the loan is converted to shares. Specifically the directors have not disclosed in any formal RNS what the terms of conversion are for the interest element of the bond. It's not easy to work out what those terms are but we can work out that the terms are incredibly onerous. Going back to the recent conversion notice: it tells us that: ”Kromek … has issued and allotted 7,830,628 new ordinary shares in the Company ("Shares") at a conversion price of 5.11 pence per Share in order to settle the exercise of convertible loan notes and repayment of interest to certain convertible loan note holders … The Partial Conversion reduces the amount owing on the convertible notes by £261,000, with £2,579,000 remaining.” But if you do the simple calculation of £261,000 / 7,830,628 then you get to a conversion price of 3.33p!!! The explanation is that the RNS disclosure above only relates to principal and doesn’t include interest. Hence 5,107,632 shares have been issued at a price of 5.11p a share to repay the principal of £261,000 ( 5,107,632 shares x 5.11p = £261,000 ) and then a further 2,722,996 shares have been issued ( 7,830,628 - 5,107,632 ) to pay an undisclosed amount of interest at an undisclosed conversion price. Having different conversion terms for the principal and interest is a new trend with convertible loans, you can find similar convertible loans with both COPL and SOU that have different conversion terms between principal and interest. There’s no benefit to having these unusual terms other than to deceive shareholders into thinking that the deal is better than it actually is. JakNife |
Posted at 02/1/2024 13:08 by supernumerary Jak - they're right down the bottom of the page...This is just the first lot - not saying anything new... ------------- T Burley 26 DECEMBER, 2023 It's tiny and still loss-making after more than a decade in business and many funding rounds. It's not to a business, it's a customer charity transferring shareholders funds to them every day year after year. If it had scaled to billions or at least a few hundred million over these decades and was ... See more... Recommend (31) Andrew Lapping 26 DECEMBER, 2023 As a long suffering shareholder, try making a profit or get out of the way and let someone else try.The company has had numerous fundraisings, pre and post IPO, at ever decreasing values. Time to make a profit Recommend (15) Jonathon Cole 26 DECEMBER, 2023 The owner is part of the problem. He has persistently avoided investing and expanding to a greater scale required to boost profitability because he , like many science based entrepreneurs, he is afraid of / doesn’t understand dilution. They dont like losing control He should have raised more fund... See more... Recommend (12) S Evans 26 DECEMBER, 2023 Kromek has consistently come back to shareholders for funds at massive discounts, no way would the CEO have been able to obtain funds elsewhere if it was not public. As a shareholder I have been Distinctly unimpressed with the CEO and the board, the CEO continues to reward himself with a bloated sal... See more... Recommend (9) Ian Caswell 26 DECEMBER, 2023 What a terrible example. After 10 years floated only £17m turnover and a massive £7m loss. Pity the poor shareholders. Looks like a very poorly run company that will eventually change management or go bust. The market has reacted exactly the way it should to a rubbish business. Recommend (9) M Hedges 26 DECEMBER, 2023 What retail investors do understand is that when it comes to return on investment, the top line by itself is meaningless. A wafer thin gross margin and an eye watering loss at the operating level are of far more interest. An extremely high cash burn and constant dilution at lower and lower prices a... See more... Recommend (6) T Nicholson 26 DECEMBER, 2023 It sounds like a very clever business but if you’re not turning profit after a decade and having had multiple funding rounds, perhaps it is the business? Recommend (5) P Norton 26 DECEMBER, 2023 Blaming the market is shooting the messenger. Prices are information and the information this share price is telling you is that this is a rubbish company. If it were any good then a private buyer would have bought it or if the management back it, why not do a MBO? Of course the market isn’t always... See more... Recommend (4) Charles Mitchell 26 DECEMBER, 2023 Not only not profitable but they have had numerous fund raising. So no wonder the market values lowly. Interesting company, but would only buy on improved financial performance. Recommend (3) Bobbie Fish 26 DECEMBER, 2023 How do you value a business that is not making a profit which is in a fast moving technology world. You need to know about the competition and demand for its products. That’s a difficult valuation to make. Any valuation is on hope and the Kromek boss possibly a salesman is the last person to value ... See more... Recommended (0) James Robinson 26 DECEMBER, 2023 A poor comment which says everything. Look in the mirror Recommend (2) |
Posted at 02/1/2024 12:22 by jaknife This is the article. Perhaps it's my settings but I can't see any reader comments.==================== Kromek boss ‘might not have listed technology company on Aim’ Arnab Basu joins other technology bosses ‘frustrated Katie Prescott, Technology Business Editor Tuesday December 26 2023, 12.01am GMT, The Times Arnab Basu, the chief executive of Kromek, argues that technology businesses that require time and investment to grow are often ignored by UK investors in favour of short-term successes The boss of Kromek has said that with hindsight he might not have listed the scanning technology business on London’s junior stock market, adding his voice to those of other British technology chief executives who complain that the City lacks understanding of the sector. The share price of the Co Durham-based company, which designs and makes high-specification materials for security and medical imaging, has fallen by more than 90 per cent since it was listed on Aim in 2013, despite Kromek increasing its revenue and market share. Arnab Basu said it was “frustrating that the company’s value isn’t recognised”. The business, which celebrated its 20th anniversary this year, made £17 million of revenue in 2022, a 44 per cent rise from the year before. However, it has yet to make a profit, suffering an adjusted pre-tax loss of £7 million in 2023, down from £7.8 million the year before. About a third of its revenue is from the United States and a fifth from Britain. Kromek is covered by only one firm of City analysts — Cavendish, part of the finnCap Group. In July, after the company’s full-year results, Mark Brewer, finnCap’s director of research, wrote: “As the only independent supplier at scale of CZT [a semiconductor] for imaging systems, we believe there is substantial strategic value in Kromek that is not reflected in the current price.” Another London technology analyst, who does not follow the stock, said: “The low end of the Aim market capitalisation spectrum can be a trap in terms of low valuations. The company capitalises a lot of development costs and has been cashflow-negative for the past two years; improving profitability and turning cash-positive will be keys to getting a higher valuation.” Reflecting on its ten years as a public company, Basu, 50, said: “We have had a difficult time in the market, where the business has grown continuously but the value recognition has declined continuously. When you’re talking to retail investors, it must be very challenging for them to really understand a small, complex business. The relationship we had with private investors was much more interactive.” He argued that technology businesses that required time and investment to grow were often ignored in favour of short-term successes. “Hardware tech is still rare in the UK. And I think if you’re not in certain segments, understanding and the pool of investors within that is reasonably limited, which creates a pressure. Kromek’s story is shared by many compatriots in the tech market.” Basu moved to Newcastle from India for his degree and stayed in the city, spinning out his doctorate from Durham University into a business that supplies medical companies, airports and security services worldwide. Kromek developed a semiconductor technology and manufacturing process that goes into a range of applications, including creating Europe’s first liquid explosive detection system, and has won its first contract with the European Space Agency. Based in Sedgefield, the company employs 150 people with offices and manufacturing facilities in Pennsylvania and California. It supplies the US Department of Homeland Security and works with Darpa, the US defence agency, producing a portfolio of products for the military in radiation detection. Among the products in the pipeline, it is developing an airborne pathogen-testing system. The company works on detection in oncology, Alzheimer’s and cardiac processes and in the analysis of airborne diseases. Another area is radiation detection and Basu said it was looking at early warnings of biological or chemical weapons being used in public areas from cities to stadiums. |
Posted at 09/5/2023 20:21 by aqc888 For some context;Pivotal year unfolding for Kromek - 18/1/22 Share price 14.5p Winners in an uncertain world - 16/5/22 Share price 9.7p Kromek’s record sales visibility is materially undervalued - 2/8/22 Share price 9.5p A biological detection winner - 11/22 Share price 8.75p This stock is about to turn world-leading technology into profit - 2/23 Analysts think this stock's share price will quadruple - 4/23 Share price 6.85p Buy into Kromek's £7.5mn open offer of new shares - today Share price 5p …. It goes back way further when share price was way way higher… “Don't worry about Kromek's revenue fall“ - 1/2019 Share price 26p |
Posted at 10/8/2022 03:36 by ark87 The shareprice was down until IC tipped it (again). Unfortunately as you can see from KMK share price performance since inception (51p to to 14p over 9 years) will be short lived unless some game changing news is on horizon which at this point seems doubtful. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
